Influence on early outcome and restenosis of urokinase before elective coronary angioplasty.
Mehan
V K
VK
Cardiology Center, University Hospital, Geneva, Switzerland.
Meier
B
B
Urban
P
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D001241:Aspirin / Q000627:therapeutic use; D003327:Coronary Disease / Q000517:prevention & control / Q000628:therapy*; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011292:Premedication; D012008:Recurrence; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D006493:Heparin; D014568:Urokinase-Type Plasminogen Activator; D001241:Aspirin